uniQure stock crashes as Huntington’s gene therapy data weaken
uniQure shares plummeted 37.3 percent after 48-month data for its Huntington disease candidate AMT-130 showed a 44 percent slowing of disease progression, down from a 75 percent slowing at 36 months. The latest results failed to meet a key statistical measure, prompting Bronstein, Gewirtz & Grossman, LLC to launch an investigation into potential securities law violations. Investors now question the long-term durability of the treatment and its likelihood of receiving regulatory approval, which are critical components of the company's rare disease business strategy.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ 48-month clinical data for AMT-130 did not meet a key statistical measure.
- ✓ Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of uniQure shareholders.
- ✓ AMT-130 data showed a 44 percent slowing of disease progression at 48 months compared to 75 percent at 36 months.
- ✓ uniQure shares dropped 37.3 percent in one day following the data release.
What changed
Bronstein, Gewirtz & Grossman, LLC is the named law firm conducting the securities investigation.
Live updates
-
Law firm probes uniQure after AMT-130 Huntington's data fails statistical measure
uniQure shares plummeted 37.3 percent after 48-month data for its Huntington disease candidate AMT-130 showed a 44 percent slowing of disease progression, down from a 75 percent slowing at 36 months. The latest results failed to meet a key statistical measure, prompting Bronstein, Gewirtz & Grossman, LLC to launch an investigation into potential securities law violations. Investors now question the long-term durability of the treatment and its likelihood of receiving regulatory approval, which are critical components of the company's rare disease business strategy.
Why it matters
uniQure previously filed an FDA application using the more optimistic 36-month data. The discrepancy between the two timeframes creates uncertainty regarding the therapy's efficacy over time. This program is a central pillar of the company's pipeline.
What is confirmed
- 48-month clinical data for AMT-130 did not meet a key statistical measure.
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of uniQure shareholders.
- AMT-130 data showed a 44 percent slowing of disease progression at 48 months compared to 75 percent at 36 months.
- uniQure shares dropped 37.3 percent in one day following the data release.
What to watch next
- FDA decision on the AMT-130 application
- Updates on the Bronstein, Gewirtz & Grossman, LLC investigation
- Further long-term durability data for AMT-130
confidence 100%Sources used for this update (2)
- simplywall.st — Will Disappointing Trial Data Change uniQure (QURE) Stock ...
- www.accessnewswire.com — Bronstein, Gewirtz & Grossman, LLC Announces an ...
-
uniQure shares plunge 37 percent on weaker Huntington drug data
uniQure shares fell 37.3 percent in a single day after the company revealed that 48-month data for its Huntington disease gene therapy candidate AMT-130 showed a 44 percent slowing of disease progression. This drop followed earlier results demonstrating a 75 percent slowing at 36 months. The weaker long-term findings triggered an investigation by a law firm into potential securities law violations by uniQure and its management regarding the disclosures. Previously, uniQure submitted an FDA application based on the stronger 36-month findings amid conflicting regulatory signals.
Why it matters
The sharp drop in share value reflects investor sensitivity to shifting efficacy measures in late-stage neurological drug trials. uniQure submitted an FDA application using the earlier 36-month data before the release of the updated 48-month results. Meanwhile, a law firm is actively investigating potential claims on behalf of uniQure purchasers following these events.
What is confirmed
- uniQure released 48-month data for its Huntington disease drug AMT-130 showing a 44 percent slowing of disease progression.
- The 48-month efficacy figure decreased from 75 percent at 36 months.
- The weaker data caused the uniQure stock to drop 37.3 percent in one day.
- uniQure previously submitted an FDA application based on the earlier 36-month data.
Still unconfirmed
- A law firm is investigating possible securities law violations by uniQure and its management related to the drug disclosures.
What to watch next
- FDA decisions regarding the regulatory application submitted by uniQure based on the 36-month data
- Developments and findings from the active law firm investigation into uniQure purchasers and management disclosures
confidence 100%Sources used for this update (4)
- baynews9.com — Two Bay area medical professionals killed in small plane crash
- pluang.com — uniQure shares plunge 37% after new trial data ... | Pluang
- pharmaphorum.com — PTC's Huntington study was positive. Why did its stock fall?
- stockanalysis.com — uniQure (QURE) Stock Price & Overview
-
uniQure Stock Struggles as Huntington’s Data and FDA Friction Persist
uniQure stock trades at US$23.14 following severe multi-month losses, including a 48 percent drop over 30 days and a 61.41 percent decline over one year, despite long-term gains over three years. Fresh Phase I/II data for the Huntington’s disease gene therapy candidate ifezuntirgene inilparvovec, also referred to as AMT-130, demonstrate continued slowing of disease progression at 36 and 48 months compared to external controls alongside a manageable safety profile. Meanwhile, the law firm Bronstein, Gewirtz and Grossman, LLC pursues an active investigation into potential claims on behalf of uniQure purchasers following conflicting regulatory signals from the FDA.
Why it matters
The company faces heavy market pressure after regulators previously declared data for the Huntington’s disease gene therapy insufficient for review and accelerated approval. This regulatory hurdle triggered analyst downgrades and sharp share price contractions before the release of the latest 36 and 48-month data. The legal investigation by Bronstein, Gewirtz and Grossman, LLC directly follows these disclosures and investor losses.
What is confirmed
- uniQure shares trade at US$23.14, with a 30-day return down 48 percent and a 1-year total shareholder return down 61.41 percent.
- Fresh Phase I/II data for the Huntington’s disease gene therapy candidate ifezuntirgene inilparvovec show continued slowing of disease progression at 36 and 48 months versus external controls.
- The law firm Bronstein, Gewirtz and Grossman, LLC initiated an investigation into potential claims on behalf of uniQure purchasers.
What to watch next
- Further updates from uniQure on its engagement with regulators regarding a path forward for the gene therapy
- Developments or potential filings resulting from the Bronstein, Gewirtz and Grossman, LLC investor investigation
confidence 100%Sources used for this update (3)
- simplywall.st — Is uniQure (QURE) Undervalued On New Huntingtons Data And FDA ...
- simplywall.st — Gene Therapy Data Could Be A Big Moment For uniQure Stock ...
- www.accessnewswire.com — Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation ...
-
uniQure Faces Investigation and Downgrade Following FDA Rejection
uniQure shares dropped another 5.9 percent following a previous 3 percent decline and a downgrade by Barclays to equal weight from overweight, as trading volume reached about 2.3 million shares. The losses follow an unexpected FDA decision declaring data for the company's Huntington's disease gene therapy, AMT-130, insufficient for approval. Amid the fallout, the law firm Bronstein, Gewirtz and Grossman, LLC announced an investigation into potential claims on behalf of uniQure purchasers. The company is currently seeking to engage with regulators to determine a path forward for the therapy after regulators indicated they are not prepared to review it.
Why it matters
The setbacks follow the release of four-year data for the AMT-130 gene therapy on September 29, which showed that the main Huntington's score lost statistical significance despite some remaining signals of daily function. uniQure previously stated that the FDA's refusal to review the therapy represents a policy change. Meanwhile, the company also reported additional 36- and 48-month Phase I/II data for the treatment, marketed as ifezuntirgene inilparvovec, which it claims shows continued slowing of disease progression versus matched external controls.
What is confirmed
- uniQure shares fell 3% in Monday trading after Barclays downgraded the stock to equal weight from overweight.
- Trading volume stood at about 2.3 million shares.
Still unconfirmed
- Bronstein, Gewirtz and Grossman, LLC is investigating potential claims on behalf of purchasers of uniQure.
What to watch next
- Regulatory engagement between uniQure and the FDA to determine a path forward for the therapy
- Developments from the legal investigation initiated by Bronstein, Gewirtz and Grossman, LLC
confidence 90%Sources used for this update (4)
- finance.yahoo.com — Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene ...
- www.accessnewswire.com — uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz ...
- economictimes.indiatimes.com — qure fda: Latest News & Videos, Photos about qure fda | The ...
- www.marketscreener.com — UniQure Shares Fall After Barclays Downgrade | MarketScreener
-
uniQure shares crash as FDA declines to review Huntington's gene therapy
uniQure stock lost more than a third of its value in a single session after the company released four-year data for its AMT-130 gene therapy on September 29. While some signals of daily function remain, the main Huntington's score lost statistical significance and the treatment effect was smaller than the three-year report. The FDA has informed uniQure it is not prepared to review the therapy, which the company suggests represents a change in policy. These developments follow a previous 24 percent drop for partner ClearPoint Neuro.
Why it matters
AMT-130, also known as ifezuntirgene inilparvovec, is an experimental treatment designed to slow the progression of Huntington's disease. The therapy's viability depends on maintaining long-term durability of the treatment effect. A failure to secure FDA review halts the current path to regulatory approval and commercialization.
What is confirmed
- uniQure shares plunged on September 29 following the release of four-year AMT-130 data.
- The four-year update showed a smaller treatment effect than the company reported at the three-year mark.
- The main Huntington's score lost statistical significance in the latest data.
- uniQure lost more than a third of its value in one session.
Still unconfirmed
- The FDA's refusal to review the therapy stems from a change in policy.
- The therapy's durability dropped from 75% to 44%.
What to watch next
- Official FDA statement regarding the reasons for blocking the review
- uniQure's formal response or appeal to the FDA decision
- Updated clinical trial protocols to address the loss of statistical significance
confidence 90%Sources used for this update (6)
- finance.yahoo.com — uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s ...
- economictimes.indiatimes.com — Why uniQure shares are sinking after AMT-130 update
- pharmaphorum.com — uniQure poleaxed as FDA blocks Huntington's therapy
- www.matterfact.com — Gene Therapy's Durability Problem as uniQure's 75% Becomes 44 ...
- www.medicaldaily.com — Huntington's Gene Therapy Still Appears to Slow Daily ...
- finance.yahoo.com — uniQure Plunges on Additional Data From Huntington's Disease ...
-
uniQure Posts 48-Month Huntington's Disease Therapy Data
uniQure released additional data from ongoing Phase I/II studies of its experimental Huntington's disease treatment, ifezuntirgene inilparvovec, also known as AMT-130. The updated readout covers 12 high-dose patients at 48 months. According to the company, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression alongside clear dose-dependent effects. The latest findings follow an earlier market reaction where shares plummeted and partner ClearPoint Neuro dropped 24 percent after the therapy missed statistical significance on a primary clinical measure.
Why it matters
The ongoing evaluation of ifezuntirgene inilparvovec tracks long-term patient outcomes for Huntington's disease, a severe neurodegenerative disorder. Evaluating the 48-month data helps researchers determine if the initial dose-dependent slowing of disease progression remains durable over time despite earlier missed statistical endpoints on primary clinical measures.
What is confirmed
- uniQure announced additional data from ongoing Phase I/II studies of ifezuntirgene inilparvovec in Huntington's disease.
- Data from 12 high-dose patients at 48 months showed both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent effects.
What to watch next
- Further clinical data releases from ongoing Phase I/II studies
- Market performance and investor reactions for uniQure and partner ClearPoint Neuro
confidence 100%Sources used for this update (4)
- en.wikipedia.org — The Alchemist (novel) - Wikipedia
- www.globenewswire.com — uniQure Announces Additional Data from Ongoing Phase I/II - GlobeNewswire
- www.goodreads.com — The Alchemist by Paulo Coelho | Goodreads
- www.wikihow.com — The Alchemist Summary: Analysis, Characters, & Life Lessons
-
uniQure Stock Plunges as Huntington's Gene Therapy Data Disappoints
Shares of gene therapy developer uniQure crashed after the company released an updated data readout for its experimental Huntington's disease treatment, ifezuntirgene inilparvovec, also known as AMT-130. Although the therapy continued to show a dose-dependent slowing of disease progression through 48 months, it failed to hit statistical significance on a primary clinical measure. The missed statistical endpoint triggered a massive sell-off among investors and sent partner ClearPoint Neuro shares down 24 percent.
Why it matters
The experimental treatment is being evaluated in an ongoing Phase I/II trial to address Huntington's disease, a severe neurodegenerative condition. While long-term data showed ongoing physiological effects, the failure to clear the statistical threshold on primary clinical measures at 48 months severely dampened market expectations. Market reactions included dramatic valuation drops for uniQure alongside a significant fall in shares of ClearPoint Neuro.
What is confirmed
- Shares of gene therapy developer uniQure N.V. cratered 64 percent Tuesday morning following an updated data readout for its experimental Huntington's disease treatment, ifezuntirgene inilparvovec (AMT-130).
- The treatment continued to show a dose-dependent slowing of disease progression, but failed to hit statistical significance on a primary clinical measure at 48 months.
- ClearPoint Neuro shares fell 24 percent following the uniQure AMT-130 trial update.
What to watch next
- Further regulatory or corporate disclosures regarding the Phase I/II trial path for AMT-130
- Additional analyses of long-term patient data from the ongoing trial
confidence 100%Sources used for this update (10)
- Fierce Biotech — uniQure stock crashes as Huntington’s gene therapy data weaken
- STAT — UniQure’s gene therapy continues to slow Huntington’s progression after four years
- Reuters — UniQure plunges as Huntington's trial data disappoints investors
- Bloomberg.com — UniQure Sinks After Worse-Than-Expected Huntington’s Results
- Yahoo Finance — ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update
- GlobeNewswire — uniQure Announces Additional Data from Ongoing Phase I/II
- finance.yahoo.com — uniQure plunges 65% as 48-month Huntington’s gene therapy ...
- blockonomi.com — uniQure (QURE) Stock Crashes 48% on Disappointing Huntington ...
- www.cafepharma.com — uniQure stock crashes as Huntington’s gene therapy data ...
- finance.yahoo.com — UniQure's Huntington's therapy fails to significantly slow ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community